Some research progress of CXCR4 antagonist AMD3100.
- Author:
Chun-Kang CHANG
1
;
Xi ZHANG
;
You-Shan ZHAO
;
Xiao LI
Author Information
1. Department of Hematology, Shanghai Jiaotong University Sixth People Hospital, Shanghai 200233, China. changchunkang7010@yahoo.cn
- Publication Type:Journal Article
- MeSH:
Heterocyclic Compounds;
pharmacology;
Receptors, CXCR4;
antagonists & inhibitors
- From:
Journal of Experimental Hematology
2011;19(3):831-834
- CountryChina
- Language:Chinese
-
Abstract:
AMD3100 (Plerixafor) is an antagonist of CXCR4, receptor for stromal cell-derived factor-1 (SDF-1).It disrupts binding of SDF-1 to CXCR4 by competing binding site, thus blocking the physiological function of SDF-1/CXCR4 axis. SDF-1/CXCR4 axis has been shown to play critical roles in stem cell mobilization, migration and homing, and in immunoregulation, inflammatory disease, autoimmune disorder, embryonic development, and tumor cell proliferation, migration and location. AMD3100 has been confined effective for the mobilization of HSC and MSC, inhibition of carcinoma growth and metastasis, suppression of some inflammatory and autoimmune disorder. Therefore, further research on AMD3100 will be helpful to understand the effects of bone marrow microenvironment on the pathogenesis of neoplasm, and to restore the traumatic tissues by mobilizing HSC effectively, that might provide a new idea and measure for the treatment of certain neoplasms. Some research progress of basic research and application on AMD3100 are summarized in this review.
